Nasal Antisepsis for C. Auris Prevention

Recruiting now · Phase 4

Conditions studied: Candida Auris Infection, Colonization, Asymptomatic

In brief

This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.

Key facts

Study ID

NCT06282510

Run by

Mary K Hayden

People needed

120

Starts

2024-01-29

Expected to finish

2028-12-01

Last updated by the study team

2025-10-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• History of C. auris colonization or infection
• Patient in a participating facility

You may not qualify if…

• History of severe allergy to iodine-based products, defined as anaphylaxis or rash
• Currently breastfeeding or pregnant
• Non-English language speaking

Where it is running

• Rush University Medical Center — Chicago, Illinois, United States (enrolling)
• RML Specialty Hospital — Chicago, Illinois, United States (enrolling)
• RML Specialty Hospital — Hinsdale, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.